Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to dateInitiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) ...

Licaminlimab (OCS-02) – An innovative TNF inhibitor specifically design for ocular inflammation : An FDA meeting in Q1 2025 confirmed the path forward for genotype-based development with Licaminlimab ...

In years 3 and 4 of treatment, faricimab was well tolerated with low rates of intraocular inflammation (1.3%) and resulted in ...

Phase II trial results indicated that treatment with the firm's antisense oligonucleotide led to stable or improved best-corrected visual acuity.

The 24-week topline results from the Phase 2 VERONA study in DME were accepted for presentation at the Retina World Congress in May 2025, which will highlight DURAVYU's potential to transform the ...

Researchers evaluated real-world data to extend treatment intervals, maintain BCVA, and achieve macular fluid resolution ...

UNITY Biotechnology reveals promising 36-week results for UBX1325 in treating diabetic macular edema, showing non-inferiority ...

I Frontera Therapeutics announced today that its proprietary recombinant adeno-associated virus (rAAV) gene therapy, FT-003 Injection, has ...

This retrospective case series involved a review of medical records at a single tertiary care center. Charbel Issa and ...

Research and development expenses for the first quarter of 2025 were $42.9 million versus $20.7 million for the comparable quarter in 2024, reflecting an increase in overall clinical expenses ...

The FDA granted regenerative medicine advanced therapy designation to 4D-150 for the treatment of diabetic macular edema, ...

D-150 is a potential backbone therapy that is designed to provide multiyear sustained delivery of anti-VEGF (aflibercept and ...